https://docs.google.com/document/d/1545C...jY/preview
Quote:12 April 2020
Raoult, D. Cohort of 1061 COVID-18 cases treated with HCQ-AZ Combination with 9 day follow-up.
IHU Méditerranée Infection, Marseille. http://covexit.com/professor-didier-raou...s-of-a-new-
hydroxychloroquine-treatment-study-on-1061-patients/
A cohort of 1061 COVID-19 patients, treated for at least 3 days with the HCQ-AZ combination and a follow-up of at least
9 days was investigated. Endpoints were death, worsening and viral shedding persistence.
From March 3rd to April 9th, 2020, 59,655 specimens from 38,617 patients were tested for COVID-19 by PCR.
Of the 3,165 positive patients placed in the care of our institute, 1061 previously unpublished patients met the inclusion
criteria for a Hydroxychloroquine –Azithromycin trial.
Mean age was 43.6 years old and 492 were male (46.4%), As in other studies, no cardiac toxicity was observed in this study.
- A good clinical outcome and virological cure was obtained in 973 patients out of a total pf 1061 patients within 10 days (91.7%).
- Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens both at IHU and in all Marseille public hospitals (p< 10-2).